Novartis pulls ahead in Q2

Sunday 25 July 2021


Novartis reported a 14% increase in group sales in the second quarter on the strength of its innovative medicines division and a rebound at the Sandoz generics unit. Sandoz had experienced weak retail demand and price competition at the start of the year, but the business was starting

Read in full with a subscription

Learn more about subscribing to MedNous.